Cleveland Clinic research has found that the blood thinner rivaroxaban significantly reduces venous thromboembolism (VTE)—a blood clot in the venous system—and VTE-related death for outpatient, high-risk cancer patients while they are taking the oral anticoagulant.
Combining ibrutinib with the CDK4/6 inhibitor palbociclib appeared to be well tolerated and active in patients with previously treated mantle cell lymphoma.
The FDA has granted a priority review to a supplemental new drug application for ivosidenib for the frontline treatment of patients IDH1-mutant acute myeloid leukemia who are ineligible for standard chemotherapy.
The 4-drug combination of rituximab, bendamustine, bortezomib, and dexamethasone was found to improve progression-free survival and demonstrated a tolerable safety profile as frontline treatment for patients with mantle cell lymphoma who are ≥65 years.
The combination of pembrolizumab plus best supportive care for the treatment of patients with advanced hepatocellular carcinoma who were previously treated with systemic therapy did not improve progression-free or overall survival compared with placebo plus best supportive care alone, missing the coprimary endpoints of the KEYNOTE-240 trial.
The FDA has granted a priority review designation to a supplemental biologics license application for pembrolizumab (Keytruda) as a treatment for patients with advanced small cell lung cancer whose disease has progressed following ≥2 prior lines of therapy.
Suman Kambhampati, MD, reflects on the emergence of data in chronic lymphocytic leukemia from the 2018 ASH Annual Meeting.
The FDA has granted a priority review designation to a new drug application for entrectinib as a treatment for select adult and pediatric patients with NTRK fusion–positive locally advanced or metastatic solid tumors, as well as patients with metastatic ROS1-positive non–small cell lung cancer.
The European Commission has approved PF-06439535 (Zirabev), a bevacizumab (Avastin) biosimilar for the treatment of patients with metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic, or recurrent non–small cell lung cancer, advanced and/or metastatic renal cell cancer, and persistent recurrent or metastatic carcinoma of the cervix.
The FDA has granted a priority review designation to polatuzumab vedotin for use in combination with bendamustine and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.
The FDA has approved the PD-1 inhibitor pembrolizumab for the adjuvant treatment of patients with high-risk stage III melanoma with lymph node involvement following complete resection.
The Centers for Medicare & Medicaid Services has proposed to cover chimeric antigen receptor T-cell therapies approved by the FDA, under “Coverage with Evidence Development."
Theresa Shao, MD, discusses the neoadjuvant and adjuvant findings with pertuzumab as well as the adjuvant use of neratinib in patients with locally advanced HER2-positive breast cancer.
Sarah B. Goldberg, MD, MPH, sheds light on the complex treatment paradigm for patients with lung cancer who have central nervous system metastases and highlights emerging treatment strategies for those with mesothelioma.
The FDA has granted a priority review designation to a supplemental biologics license application for the combination of pembrolizumab and axitinib as a frontline treatment for patients with advanced renal cell carcinoma.
The 5α-reductase inhibitor finasteride (Proscar), an agent commonly used to treat lower urinary tract problems and baldness in men, was found to be safe and effective in reducing the risk of prostate cancer.
Julie R. Brahmer, MD, discusses advances made with immunotherapy in the lung cancer space, highlights challenges that still need to be addressed, and sheds light on ongoing research designed to determine treatment approaches beyond PD-1/PD-L1 and CTLA-4 inhibition
First- and second-generation TKIs confer a significant survival benefit for patients with chronic-phase chronic myeloid leukemia (CP-CML)—so much so, that treatment discontinuation has become a viable option for select patients.
Edward B. Garon, MD, discusses the landscape of EGFR-targeted therapy in non–small cell lung cancer.
Stereotactic body radiation therapy has been found to be a safe and effective option for patients with low- and intermediate-risk prostate cancer.
Jesus Berdeja, MD, discusses emerging standards of care in transplant-eligible and -ineligible patients with newly diagnosed multiple myeloma.
Jordan Gauthier, MD, MSc, discusses retrospective results of concurrent ibrutinib and JCAR014 and where chimeric antigen receptor T-cell research is headed for patients with chronic lymphocytic leukemia.
The FDA has approved a split-dosing regimen of daratumumab for patients with multiple myeloma, providing physicians the option to split the first infusion of the CD38-directed monoclonal antibody over 2 consecutive days or complete in a single session.
Victor A. Chow, MD, discusses the next steps in understanding how to treat patients with large B-cell lymphomas who progress after chimeric antigen receptor T-cell therapy.
Heather Wakelee, MD, shares insight on the current landscape of lung cancer and discussed how immunotherapy and targeted therapy can be improved for patients with non–small cell lung cancer.
